Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: Systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 108, Issue 10, 2013, Pages 1566-1574

  Ford, Alexander C ^a,b   Brenner, Darren M ^c   Schoenfeld, Philip S ^d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; LUBIPROSTONE; METHADONE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; OPIATE; OXYCODONE; PLACEBO; PRUCALOPRIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANALGESIA; COCHRANE LIBRARY; CONSTIPATION; DEFECATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TREATMENT FAILURE; EMBASE; HEADACHE; HUMAN; MEDLINE; META ANALYSIS; METHADONE TREATMENT; MULTICENTER STUDY (TOPIC); NAUSEA; OPIOID INDUCED CONSTIPATION; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ALPROSTADIL; ANALGESICS, OPIOID; BENZOFURANS; CONSTIPATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PEPTIDES; PIPERIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID, MU;

EID: 84885477508     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.169     Document Type: Review

References (37)

1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 1582-91
2. Talley NJ, Jones M, Nuyts G et al. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003; 98: 1107-11
3. Kaufman PN, Krevsky B, Malmud LS et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988; 94: 1351-6
4. Cook SF, Lanza L, Zhou X et al. Gastrointestinal side Effects in chronic opioid users: Results from a population-based survey. Aliment Pharmacol Ther 2008; 27: 1224-32
5. Bell T, Panchal SJ, Miaskowski C et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Med 2009; 10: 35-42
6. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: Fi ndings from the National Health and Wellness Survey. J Opioid Manag 2009; 5: 137-44
7. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (5A suppl): 11S - 8S.
8. Candy B, Jones L, Goodman ML et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011; CD003448
9. Michna E, Blonsky ER, Schulman S et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: A randomized controlled study. J Pain 2011; 12: 554-62
10. Lowenstein O, Leyendecker P, Hopp M et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: A randomised controlled trial. Expert Opin Pharmacother 2009; 10: 531-43
11. Jansen J - P, Lorch D, Langan J et al. A randomized, placebo-controlled phase 3 trial (study sb-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011; 12: 185-93
12. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idipathic constipation: Systematic review and meta-analysis. Gut 2011; 60: 209-18
13. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: Version 5.0.2. www.cochrane-handbook.org. 2009
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88
15. Higgins JPT, Th ompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60
16. Egger M, Davey-Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34
17. Sterne JA, Sutton AJ, Ioannidis JP et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J 2011; 343: D4002.]
18. Yuan C - S, Foss JF, O ' Connor M et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA 2000; 283: 367-72
19. Th omas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358: 2332-43
20. Slatkin N, Th omas J, Lipman AG et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009; 7: 39-46
21. Anissian L, Schwartz HW, Vincent K et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: Phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med 2012; 7: 67-72
22. Rauck RL, Peppin JF, Israel RJ et al. Oral methylnaltrexone for the treatment of opioid-induced constipation in patients with noncancer pain. Gastroenterology 2012; 142 (Suppl1): S160
23. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23: 48-53
24. Meissner W, Leyendecker P, Mueller-Lissner S et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. J Pain 2009; 13: 56-64
25. Simpson K, Leyendecker P, Hopp M et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24: 3503-12
26. Paulson DM, Kennedy DT, Donovick RA et al. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioidinduced bowel dysfunction - A 21-day treatment-randomized clinical trial. J Pain 2005; 6: 184-92
27. Webster L, Jansen JP, Peppin J et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioidinduced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-fi nding study in subjects taking opioids for chronic non-cancer pain. Pain 2008; 137: 428-40
28. Irving G, Penzes J, Ramjattan B et al. A randomized, placebo-controlled phase 3 trial (study sb-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011; 12: 175-84
29. Cryer BL, Katz S, Vallejo R et al. A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioidinduced bowel dysfunction in patients with chronic, non-cancer pain. Gastroenterology 2010; 138 (Suppl1): S129
30. Mazen Jamal M, Mareya SM, Woldegeorgis F et al. Lubiprostone signifi - cantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: Results from a phase 3, randomized, double-blind, placebo-controlled clinical trial. Gastroenterology 2012; 142 (Suppl1): S144 - 5
31. Sloots CE, Rykx A, Cools M et al. Effi cacy and safety of prucalopride in patients with chronic noncancer pain suff ering from opioid-induced constipation. Dig Dis Sci 2010; 55: 2912-21
32. Barish CF, Drossman D, Johanson JF et al. Effi cacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010; 55: 1090-7
33. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate effi cacy and safety. Aliment Pharmacol Ther 2007; 25: 1351-61
34. Johanson JF, Morton D, Geene J et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170-7
35. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. Br Med J 2001; 323: 42-6
36. Dunlop W, Uhl R, Khan I et al. Quality of life benefi ts and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: A UK cost-utility analysis. J Med Econ 2012; 15: 564-75
37. Dorn SD, Meek PD, Shah ND. Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin Gastroenterol Hepatol 2011; 9: 1078-85